{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001751","form_type":"8-K","ticker":"TDOC","cik":"0001477449","company_name":"Teladoc Health, Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.169914+00:00","generated_at":"2026-06-19T04:41:25.395497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Teladoc Health Q4 revenue up 15% to $637.7M; net loss of $3.81B on $3.77B goodwill impairment","bullets":["Full-year 2022 revenue $2.41B (+18% YoY); net loss $13.66B ($84.60/share) driven by $13.4B non-cash goodwill impairment.","Q4 adjusted EBITDA $94.1M (+22% YoY); full-year adjusted EBITDA $246.5M (-8% YoY).","BetterHelp segment Q4 revenue $277.0M (+29% YoY); Integrated Care Q4 revenue $357.1M (+6% YoY).","Full-year free cash flow $16.5M vs $130.1M in 2021; cash position $918.2M at Dec 31, 2022.","Q1 2023 revenue guidance $610-625M; full-year 2023 revenue $2.55-2.675B, adjusted EBITDA $275-325M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001751","json":"https://secwatch.observer/filing/0001558370-23-001751.json","markdown":"https://secwatch.observer/filing/0001558370-23-001751.md","text":"https://secwatch.observer/filing/0001558370-23-001751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477449/000155837023001751/0001558370-23-001751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477449/000155837023001751/tdoc-20230222x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:41:25.395497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e26e26ffa57ba1b44481786164320905fa1cd0d","claim":"Teladoc Health, Inc. reported Full Year 2022 results: revenue $2,406.8 million, net income ($13,659.5 million), EPS ($84.60) per share.","evidence_excerpt":"Full Year Ended December 31, 2022 Revenue increased 18% to $2,406.8 million from $2,032.7 million for the year ended December 31, 2022 (“Full-Year 2022”). Access fees revenue grew 21% to $2,103.8 million, and other revenue grew 4% to $303.0 million. U.S. revenues and International revenues each grew 18% to $2,101.0 million and $305.8 million, respectively. Revenue increased 6% to $1,373.9 million for the Integrated Care segment and increased 41% to $1,019.6 million for the BetterHelp segment for Full-Year 2022. Non-cash goodwill impairment charges of $13.4 billion were recorded for Full-Year 2022. The non-cash charges had no impact on the provision for income taxes. Net loss totaled $13,659.5 million, or ($84.60) per share, for the year ended December 31,2022, compared to $428.8 million, or ($2.73) per share, for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477449/000155837023001751/0001558370-23-001751-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"$2,406.8 million"},{"label":"Net income","value":"($13,659.5 million)"},{"label":"EPS","value":"($84.60) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e7c3f4b70236d2527594f49a043bd020c2cb129f","claim":"Teladoc Health, Inc. reported Fourth Quarter 2022 results: revenue $637.7 million, net income ($3,810.1 million), EPS ($23.49) per share.","evidence_excerpt":"Fourth Quarter 2022 Revenue increased 15% to $637.7 million from $554.2 million in the fourth quarter of 2021. Access fees revenue grew 16% to $553.7 million and other revenue grew 10% to $84.0 million. U.S. Revenues grew 15% to $554.4 million and International revenues grew 17% to $83.3 million. Revenue increased 6% to $357.1 million for the Teladoc Health Integrated Care (“Integrated Care”) segment and increased 29% to $277.0 million for the BetterHelp segment in the fourth quarter of 2022. See note (9) in the Notes section that follows for further information regarding segment reporting. Non-cash goodwill impairment charges of $3.8 billion were recorded in the fourth quarter of 2022. The non-cash charges had no impact on the provision for income taxes. Net loss totaled $3,810.1 million, or ($23.49) per share, for the fourth quarter of 2022, compared to $11.0 million, or ($0.07) per share, for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477449/000155837023001751/0001558370-23-001751-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2022"},{"label":"Revenue","value":"$637.7 million"},{"label":"Net income","value":"($3,810.1 million)"},{"label":"EPS","value":"($23.49) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}